SOX2 Gene: SRY-Box Transcription Factor 2 - Function, Disease Associations, and Expression
A comprehensive biomedical overview of the SOX2 gene, including its genomic context, protein function, associated diseases, tissue expression, and mutation landscape.
Gene Information Card
| Symbol | SOX2 |
|---|---|
| Full Name | SRY-box transcription factor 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 3q26.33 |
| NCBI Gene ID | 6657 ncbi.nlm.nih.gov/gene/6657 |
| Ensembl ID | ENSG00000181449 |
| UniProt ID | P48431 |
| OMIM ID | 184429 |
| HGNC ID | 11195 |
| Aliases | ANOP3, MCOPS3, Sox-2, ysb |
Description
The SOX2 gene encodes a member of the SRY-related HMG-box (SOX) family of transcription factors. This protein is a critical regulator of embryonic development, playing an essential role in the maintenance of pluripotency in embryonic stem cells and the determination of cell fate in multiple tissues, particularly the central nervous system, eye, and inner ear. SOX2 functions as a transcription factor by binding to DNA via its high-mobility group (HMG) domain, thereby regulating the expression of target genes involved in development. Heterozygous mutations in SOX2 are a leading cause of bilateral anophthalmia and severe microphthalmia, a condition known as SOX2 anophthalmia syndrome. Beyond developmental roles, SOX2 is also implicated in various cancers, where its dysregulation can contribute to tumorigenesis and cancer stem cell maintenance.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Anophthalmia/Microphthalmia, Isolated 3 (MCOPS3) | Heterozygous loss-of-function mutations, including whole gene deletions, frameshift, and nonsense mutations, lead to haploinsufficiency. This reduced dosage disrupts the transcriptional networks required for early eye field development, resulting in severe ocular malformations. | OMIM 206900; ClinVar; PMID: 16411226 |
| SOX2 Anophthalmia Syndrome | De novo heterozygous pathogenic variants in SOX2 cause this syndromic form of anophthalmia, often accompanied by other developmental anomalies such as brain malformations (e.g., hippocampal abnormalities), pituitary dysfunction, and intellectual disability. | OMIM 206900; PMID: 16411226 |
| Optic Nerve Hypoplasia and Abnormalities | Pathogenic SOX2 variants can lead to variable optic nerve involvement, including hypoplasia, as part of the spectrum of ocular developmental defects. | ClinVar; PMID: 16411226 |
| Sensorineural Hearing Loss | SOX2 is crucial for inner ear development. Mutations can cause hearing impairment, which is a recognized feature of SOX2 anophthalmia syndrome. | PMID: 16411226 |
| Pituitary Gland Dysfunction | SOX2 is expressed in the developing pituitary gland. Mutations can lead to hypopituitarism, manifesting as growth hormone deficiency and other hormonal imbalances. | PMID: 16411226 |
| Cancer (Various) | SOX2 is overexpressed in several cancers, including glioblastoma, lung, breast, and prostate cancers. It acts as an oncogene by promoting cancer stem cell self-renewal, proliferation, and metastasis. In some contexts, it can also act as a tumor suppressor. | COSMIC; PMID: 23201751 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Esophagus | 31.2 | High |
| Salivary Gland | 20.1 | Medium |
| Thyroid Gland | 15.3 | Medium |
| Lung | 12.4 | Medium |
| Testis | 10.5 | Medium |
| Brain - Cortex | 8.7 | Low |
| Cervix, Uterine | 7.9 | Low |
| Prostate | 6.1 | Low |
| Liver | 1.2 | Not detected |
| Heart Muscle | 0.8 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| NTERA-2 (Pluripotent Embryonal Carcinoma) | High | SOX2 is a core pluripotency factor, highly expressed in this stem cell model. |
| H1-hESC (Human Embryonic Stem Cell) | High | Essential for maintaining pluripotency and self-renewal. |
| A549 (Lung Carcinoma) | Medium | Overexpressed in a subset of lung cancers, contributing to tumorigenicity. |
| U-87 MG (Glioblastoma) | Medium | Expressed in glioma stem-like cells, associated with tumor aggressiveness. |
| MCF-7 (Breast Carcinoma) | Low | Expression is variable but can be detected in a subset of breast cancer cell lines. |
| K-562 (Chronic Myelogenous Leukemia) | Not detected | SOX2 expression is generally low or absent in this hematopoietic cell line. |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.70dupG (p.Ala24GlyfsTer65) | Frameshift | Pathogenic | Loss-of-function; leads to a truncated protein and haploinsufficiency, causing anophthalmia. |
| c.480delA (p.Gly161AlafsTer19) | Frameshift | Pathogenic | Loss-of-function; results in a premature stop codon, causing severe ocular defects. |
| c.70A>T (p.Lys24Ter) | Nonsense | Pathogenic | Loss-of-function; introduces a premature stop codon, leading to a non-functional protein. |
| Whole Gene Deletion | Copy Number Variant | Pathogenic | Loss-of-function; complete deletion of one allele results in haploinsufficiency. |
| c.959G>A (p.Arg320His) | Missense | Pathogenic | Loss-of-function; disrupts the transactivation domain, impairing its ability to activate target gene transcription. |
| c.541C>T (p.Arg181Cys) | Missense | Pathogenic | Loss-of-function; affects the HMG domain, reducing DNA binding affinity. |
Mutation functional classification
Loss of Function (LOF)
The predominant mechanism for SOX2-associated developmental disorders. Loss-of-function mutations, including nonsense, frameshift, and whole-gene deletions, result in haploinsufficiency. This means a single functional copy of the gene is insufficient to drive normal development, particularly of the eye and brain. Missense mutations can also cause loss-of-function by disrupting the DNA-binding HMG domain or the transactivation domain.
Gain of Function (GOF)
In the context of cancer, SOX2 can exhibit gain-of-function behavior through overexpression or amplification. This leads to increased transcriptional activity of its target genes, promoting cell proliferation, survival, and stemness. However, this is typically due to increased gene copy number or aberrant transcriptional regulation rather than activating mutations in the coding sequence.
Dominant Negative (DN)
While less common, some missense mutations in the HMG domain can exert a dominant-negative effect. The mutant protein can still dimerize with wild-type SOX2 or compete for DNA binding sites, interfering with the function of the remaining wild-type allele. This mechanism is proposed for certain mutations that cause a more severe phenotype than simple haploinsufficiency.
View complete mutation data：
Gene Ontology (GO)
| • DNA-binding transcription factor activity | • RNA polymerase II cis-regulatory region sequence-specific DNA binding |
| • Chromatin binding | • Transcription cis-regulatory region binding |
| • Protein binding | • Regulation of DNA-templated transcription |
| • Positive regulation of transcription by RNA polymerase II | • Negative regulation of transcription by RNA polymerase II |
| • Cell differentiation | • Nervous system development |
| • Eye development | • Inner ear development |
| • Stem cell population maintenance | • Regulation of cell population proliferation |
Pathways
• Pluripotency of Embryonic Stem Cells
• Signaling pathways regulating pluripotency of stem cells
• Developmental Biology
• Transcriptional Regulation of Pluripotent Stem Cells
• Retinoic acid signaling pathway (involved in neural differentiation)
Protein Summary
The SOX2 protein is a 317-amino acid transcription factor that belongs to the SOX (SRY-related HMG-box) family. It contains a highly conserved high-mobility group (HMG) domain that mediates sequence-specific DNA binding to the motif (A/T)(A/T)CAA(A/T)G. The protein also possesses a C-terminal transactivation domain. SOX2 functions as a key regulator of development by forming complexes with other transcription factors, such as OCT4 (POU5F1) and NANOG, to control the expression of genes involved in maintaining pluripotency and directing cell fate decisions. It is essential for the self-renewal of embryonic stem cells and plays critical roles in the development of the neuroectoderm, lens, and inner ear. In adult tissues, SOX2 is expressed in various stem and progenitor cell populations, where it contributes to tissue homeostasis and regeneration. Dysregulation of SOX2 is a hallmark of several cancers, where it can promote tumor initiation, progression, and therapy resistance.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SOX21 Knockout HEK293 Cell Line | EDJ-KQ7312 | Human | 11166 | Details Get a Quote |
| QSOX2 Knockout HEK293 Cell Line | EDJ-KQ14973 | Human | 169714 | Details Get a Quote |
| SOX2 Knockout HEK293 Cell Line | EDJ-KQ17904 | Human | 6657 | Details Get a Quote |
| SOX2 Knockout A-549 Cell Line | EDJ-KQ19906 | Human | 6657 | Details Get a Quote |
| SOX21 Knockout A-549 Cell Line | EDJ-KQ32373 | Human | 11166 | Details Get a Quote |
| QSOX2 Knockout A-549 Cell Line | EDJ-KQ45461 | Human | 169714 | Details Get a Quote |
| QSOX2 Knockout HCT 116 Cell Line | EDJ-KQ45462 | Human | 169714 | Details Get a Quote |
| QSOX2 Knockout HeLa Cell Line | EDJ-KQ45463 | Human | 169714 | Details Get a Quote |
| SOX2 Knockout HeLa Cell Line | EDJ-KQ54536 | Human | 6657 | Details Get a Quote |
| SOX21 Knockout HeLa Cell Line | EDJ-KQ55590 | Human | 11166 | Details Get a Quote |
| SOX2 Knockout HCT 116 Cell Line | EDJ-KQ71496 | Human | 6657 | Details Get a Quote |
| SOX21 Knockout HCT 116 Cell Line | EDJ-KQ72536 | Human | 11166 | Details Get a Quote |
Displaying Records 1 To 12 Of 12 Records
